Quidel Ortho Corp QDEL
We take great care to ensure that the data presented and summarized in this overview for QuidelOrtho Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding QDEL
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD11.4MShares$292 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.75MShares$172 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY6.14MShares$157 Million6.15% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$125 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA3.81MShares$97.4 Million0.03% of portfolio
-
Aqr Capital Management LLC Greenwich, CT2.66MShares$67.8 Million0.1% of portfolio
-
State Street Corp Boston, MA2.19MShares$55.9 Million0.0% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO1.89MShares$48.3 Million1.21% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.82MShares$46.4 Million0.02% of portfolio
-
American Century Companies Inc Kansas City, MO1.59MShares$40.6 Million0.04% of portfolio
Latest Institutional Activity in QDEL
Top Purchases
Top Sells
About QDEL
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Insider Transactions at QDEL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 15
2025
|
Kenneth F Buechler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,215
+8.29%
|
$138,225
$15.74 P/Share
|
Jun 30
2025
|
Michelle A. Hodges Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,030
-17.11%
|
$168,840
$28.82 P/Share
|
Jun 30
2025
|
Michelle A. Hodges Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,873
+25.2%
|
-
|
Jun 30
2025
|
Philip D. Mc Lellan Chief Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,951
-12.79%
|
$54,628
$28.82 P/Share
|
Jun 30
2025
|
Philip D. Mc Lellan Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,749
+23.74%
|
-
|
Jun 30
2025
|
Joseph M Busky Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,883
-23.92%
|
$276,724
$28.82 P/Share
|
Jun 30
2025
|
Joseph M Busky Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,367
+34.09%
|
-
|
Jun 01
2025
|
Joseph M Busky Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,466
-11.0%
|
$73,980
$30.67 P/Share
|
Jun 01
2025
|
Joseph M Busky Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,392
+19.4%
|
-
|
May 25
2025
|
Michelle A. Hodges Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
214
-0.91%
|
$6,206
$29.74 P/Share
|
May 25
2025
|
Michelle A. Hodges Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
420
+1.75%
|
-
|
May 25
2025
|
Philip D. Mc Lellan Chief Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
151
-1.42%
|
$4,379
$29.74 P/Share
|
May 25
2025
|
Philip D. Mc Lellan Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
420
+3.79%
|
-
|
May 24
2025
|
Evelyn S Dilsaver Director |
BUY
Grant, award, or other acquisition
|
Direct |
482
+2.21%
|
-
|
May 24
2025
|
Ann D Rhoads Director |
BUY
Grant, award, or other acquisition
|
Direct |
655
+2.24%
|
-
|
May 22
2025
|
Kenneth J Widder Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,929
+12.64%
|
-
|
May 22
2025
|
Joseph D Wilkins Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,929
+29.99%
|
-
|
May 22
2025
|
Mary Lake Ph D Polan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,929
+29.75%
|
-
|
May 22
2025
|
Ann D Rhoads Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,929
+26.58%
|
-
|
May 22
2025
|
Matthew Strobeck Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,929
+21.71%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 149K shares |
---|---|
Open market or private purchase | 6.03K shares |
Exercise of conversion of derivative security | 12.5K shares |
Payment of exercise price or tax liability | 42.7K shares |
---|---|
Open market or private sale | 10.6M shares |